This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Agilent Technologies Joins Forces With Baylor College Of Medicine To Provide Customized CGH Microarrays For Cancer, Prenatal And Postnatal Research

Stocks in this article: A

Agilent Technologies Inc. (NYSE: A) has announced it is collaborating with Baylor College of Medicine’s Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor’s data-rich expertise in genetics research with Agilent’s microarray manufacturing capabilities to enable advanced discoveries in cancer and cytogenetics research. The collaboration announcement was delivered at the American Society of Human Genetics conference in Boston last month.

“Designing arrays of this complexity has been an enormous effort at Baylor College of Medicine, and we are excited to partner with Agilent to share the designs with laboratories in the U.S. and internationally,” said T. Brandon Perthuis, director of business development at the BCM Medical Genetic Laboratories.

“Originally focused on micro-deletions and micro-duplications, our current designs have been continually improved over the past 10 years and are now highly robust, with the ability to detect exon-level deletions and duplications,” he said. “Our exon array targets approximately 1,700 genes and includes probes used for SNP analysis for the detection of AOH and UPD [absence of heterozygosity and uniparental disomy].”

“After years of intense study, we are proud to join with Baylor—a global leader in cancer and cytogenetics research—to provide researchers with these powerful new tools for disease research,” said Jacob Thaysen, vice president and general manager for Agilent’s Diagnostics and Genomics business.

Agilent manufactures a broad selection of microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide fluorescent in situ hybridization. The company’s human genome CGH microarrays are available in multiple formats with bundling options available.

About the Medical Genetics Laboratories at Baylor College of Medicine

For over 40 years, the Medical Genetics Laboratories at Baylor College of Medicine has been dedicated to providing the medical genetics community with comprehensive research and genetic testing services relevant to twenty-first century medicine.

About Agilent in Genomics

Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex offers a same-day sample-to-sequencer workflow; SureSelect can accurately capture whole exomes and whole methylomes in a single reaction. These are just two products arising from Agilent’s expertise in synthesizing custom complex mixtures of long oligonucleotides gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide fluorescent in situ hybridization. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanlyzer to measure sample quality, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs